Xetra
15.04.26 | 17:35
48,855 Euro
-1,52 % -0,755
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 49,085 | 49,235 | 21:56 | |
| 49,055 | 49,255 | 21:55 |
► 15.04.: | | | | | | | | |
► 14.04.: | | | | | | | | |
► Aktueller BRISTOL-MYERS SQUIBB Börsenkurs + Xetra-Orderbuch
► 14.04.: | | | | | | | | |
► Aktueller BRISTOL-MYERS SQUIBB Börsenkurs + Xetra-Orderbuch
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 55,40 | 60 | |||
| 54,30 | 100 | |||
| 53,00 | 60 | |||
| 49,635 | 9 | |||
| 49,625 | 9 | |||
| 49,615 | 9 | |||
| 49,180 | 160 | |||
| 49,175 | 1.616 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/brm.htm [/URL] | ||||
| 1.616 | 49,015 | |||
| 160 | 48,980 | |||
| 9 | 48,575 | |||
| 9 | 48,565 | |||
| 9 | 48,555 | |||
| 110 | 36,600 | |||
| 1.093 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 3.006 | 0,673 | 2.023 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:28:35 | 48,855 | 5 |
| 17:10:51 | 48,720 | 246 |
| 17:10:48 | 48,720 | 50 |
| 17:10:19 | 48,720 | 100 |
| 14:42:41 | 49,185 | 116 |
| 14:42:41 | 49,190 | 124 |
| Tagesumsatz Xetra | -0,755 -1,52 % | 741 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20:10 | Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition? | 6 | Zacks | ||
| 18:46 | Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers | 2 | BioPharma Dive | ||
| 17:30 | Raymond James reiterates Market Perform on Bristol-Myers stock | 13 | Investing.com | ||
| Mo | Bristol Myers Squibb evolves and expands multiple myeloma programme | 12 | PMLiVE | ||
| BRISTOL-MYERS SQUIBB Aktie jetzt für 0€ handeln | |||||
| Fr | BMY Gains 10% Year to Date: Should You Buy, Sell or Hold the Stock? | 14 | Zacks |
1 2 3 4 5 Weiter >>
425 Nachrichten in den letzten 12 Monaten
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 13:42 | Tilray Brands, Inc.: Tilray Brands Accelerates Next Phase of Global Growth and Market Leadership | GlobeNewswire (Europe) | NEW YORK and LEAMINGTON, Ontario, April 15, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc.?("Tilray", "our", "we" or the "Company") (NASDAQ: TLRY; TSX: TLRY), a global lifestyle and consumer packaged... ► Artikel lesen | |
| 14:10 | Teva Pharmaceutical Industries Ltd: Teva Launches Home Ground Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners | GlobeNewswire (Europe) | For people living with schizophrenia who may find daily disease management overwhelming due to fragmented support and resources, Home Ground Schizophrenia Community is a centralized destination that... ► Artikel lesen | |
| 13:06 | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications | GlobeNewswire (Europe) | Dr. Dennis K. McBride, PhD (CAPT, Medical Service Corps, US Navy, Ret., Distinguished Research Fellow, National Defense University, and former senior executive, Office Secretary of Defense) to serve... ► Artikel lesen | |
| 15:04 | Wayfinder Biosciences, Inc.: Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase | PR Newswire | SEATTLE, April 15, 2026 /PRNewswire/ -- Wayfinder Biosciences, a biotechnology company using small molecules to target undruggable proteins at the RNA level, today... ► Artikel lesen | |
| 14:10 | Boehringer Ingelheim Limited: Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3-targeting T-Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | GlobeNewswire (Europe) | Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3-targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).
Phase... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BRISTOL-MYERS SQUIBB COMPANY finden Sie auf Wallstreet Online.